NCT04923893: Phase 3 - VRd followed by Cilta-cel Vs VRd f/b Rd - NDMM- (No ASCT planned) CARTITUDE-5
NCT05014412: Phase 1/2: Elranatamab in MM That Has Come Back or Has not responded - MagnetisMM-9
NCT04975997: Phase 3: IberDd Versus DVd in Participants With Relapsed Refractory Myeloma - EXCALIBER
NCT04935580: Phase 1/2: Study of FasT CAR-T GC012F Injection in High Risk TE NDMM Patients
NCT04798586: Phase 1: MAGNETISMM-2: Study of Elranatamab (PF-06863135) in Japanese Patients Myeloma
NCT04773522: Phase 1 - JNJ-64407564 in Japanese Participants With Relapsed or Refractory Myeloma
NCT04735575: Phase 1/2: Study of EMB-06 in Participants With Relapsed or Refractory Myeloma
NCT04634552: Phase 2 - A Study of Talquetamab in Participants With Refractory Multiple Myeloma
NCT04570631: Phase 1: Eftozanermin Alfa (ABBV-621) + Bortezomib and Oral Dexamethasone RRMM
NCT04674514: Phase 1/2: APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS RRMM Myeloma
NCT04458831: A Non-interventional, Multinational, Observational study With Isatuximab in RRMM
NCT04512235: Phase 3: To Evaluate Effectiveness & Safety of CAEL-101 in Stage IIIa AL Amyloidosis
NCT04398680: Phase 1: Belantamab Mafodotin With Normal & Impaired Hepatic Function (DREAMM 13) RRMM
NCT04246047: Phase 3: Belantamab Mafodotin, Bortezomib and Dex RRMM Myeloma (DREAMM 7)
NCT04504825: Phase 3: Efficacy & Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis
NCT04557150: Phase 1: Safety and Pharmacokinetics of Escalating Doses of RO7425781 RRMM Myeloma
NCT04541368: Phase 1: A Study of CS1-targeted CAR-T Cells Therapy for RRMM After BCMA CAR-T Thaerapy
NCT04484623: Phase 3 - Belantamab Mafodotin & Pom/Dex (Pd) Vs Bortezomib & Pd in Ref. MM (DREAMM 8)
NCT04586426: Phase 1b - Talquetamab and Teclistamab in Relapsed or Refractory Multiple Myeloma